JIDINUM 100 mg FILM-COATED TABLETS

Introduction

Package Leaflet: Information for the Patient

Jidinum 25 mg film-coated tablets EFG

Jidinum 50 mg film-coated tablets EFG

Jidinum 100 mg film-coated tablets EFG

sitagliptin

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

• Keep this leaflet, you may need to read it again.
• If you have any further questions, ask your doctor, pharmacist, or nurse.
• This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
• If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

Contents of the pack and other information

1. What is Jidinum and what is it used for
2. What you need to know before you take Jidinum
3. How to take Jidinum
4. Possible side effects
5. Storage of Jidinum

1. Contents of the pack and other information

1. What is Jidinum and what is it used for

Jidinum contains the active substance sitagliptin which belongs to a class of medicines called DPP-4 inhibitors (dipeptidyl peptidase-4 inhibitors) that reduce blood sugar levels in adult patients with type 2 diabetes mellitus.

This medicine helps to increase the amount of insulin produced after a meal and decreases the amount of sugar produced by the body.

Your doctor has prescribed this medicine to help you reduce your blood sugar level, which is too high due to your type 2 diabetes. This medicine can be used alone or in combination with other medicines (insulin, metformin, sulfonylureas, or glitazones) that reduce blood sugar levels, and that you may already be taking for your diabetes, together with a diet and exercise program.

What is type 2 diabetes?

Type 2 diabetes is a condition where your body does not produce enough insulin, and the insulin that it does produce does not work as well as it should. Your body may also produce too much sugar. When this happens, sugar (glucose) builds up in the blood. This can cause serious medical problems, such as heart disease, kidney disease, blindness, and amputation.

2. What you need to know before you take Jidinum

Do not takeJidinum

• if you are allergic to sitagliptin or any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions

There have been reports of pancreatitis (inflammation of the pancreas) in patients taking sitagliptin (see section 4).

If you notice blisters on your skin, it may be a sign of a disease called bullous pemphigoid. Your doctor may ask you to stop taking this medicine.

Tell your doctor if you have or have had:

• a disease of the pancreas (such as pancreatitis)
• gallstones, alcohol dependence, or very high levels of triglycerides (a type of fat) in the blood. These medical conditions may increase your risk of developing pancreatitis (see section 4)

Children and adolescents

Children and adolescents under 18 years should not use this medicine. It is not effective in children and adolescents aged between 10 and 17 years. It is not known if this medicine is safe and effective when used in children under 10 years.

Other medicines and Jidinum

Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.

In particular, tell your doctor if you are taking digoxin (a medicine used to treat irregular heartbeat and other heart problems). Your doctor may need to check the level of digoxin in your blood if you are taking this medicine.

Pregnancy andbreast-feeding

If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

It is not known if this medicine passes into breast milk. You should not take this medicine if you are breast-feeding or planning to breast-feed.

Driving and using machines

This medicine has no or negligible influence on the ability to drive and use machines. However, dizziness and somnolence have been reported, which may affect your ability to drive or use machines.

Also, taking this medicine with sulfonylureas or insulin may cause hypoglycemia, which may affect your ability to drive or use machines or work without a secure support.

Jidinum contains sodium

This medicine contains less than 23 mg of sodium (1 mmol) per tablet; this is essentially "sodium-free".

3. How to take Jidinum

Take this medicine exactly as your doctor has told you. If you are not sure, ask your doctor or pharmacist.

The recommended dose is:

• one 100 mg film-coated tablet
• once a day
• by mouth

If you have kidney problems, your doctor may prescribe a lower dose (such as 25 mg or 50 mg).

You can take this medicine with or without food and drink.

Your doctor may prescribe this medicine alone or with other medicines that also reduce blood sugar levels.

Diet and exercise can help your body use sugar better. It is important that you follow the diet and exercise recommended by your doctor while taking this medicine.

If you take more Jidinum than you should

If you take more of this medicine than you should, contact your doctor immediately.

If you forget to takeJidinum

If you forget to take a dose, take it as soon as you remember. If you do not remember until the time for the next dose, then skip the missed dose and continue with your regular schedule. Do not take a double dose of this medicine.

If you stop taking Jidinum

Keep taking this medicine while your doctor tells you to, so that you can continue to control your blood sugar level. You should not stop taking this medicine without first talking to your doctor.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

STOPtaking sitagliptin and contact a doctor immediately if you notice any of the following serious side effects:

• Severe and persistent abdominal pain (in the stomach area) that may radiate to the back, with or without nausea and vomiting, as these may be signs of pancreatitis.

If you have a severe allergic reaction (frequency not known), including skin rash, urticaria, blisters on the skin/exfoliative skin conditions, and swelling of the face, lips, tongue, and throat that may cause difficulty breathing or swallowing, stop taking this medicine and contact your doctor immediately. Your doctor will prescribe a medicine to treat the allergic reaction and change your diabetes medicine.

Some patients experienced the following side effects after adding sitagliptin to their treatment with metformin:

Common(may affect up to 1 in 10 people): low blood sugar, nausea, flatulence, vomiting

Uncommon(may affect up to 1 in 100 people): stomach pain, diarrhea, constipation, somnolence

Some patients experienced the following side effects when they started taking sitagliptin and metformin together:

Common:different types of stomach discomfort

Some patients experienced the following side effects while taking sitagliptin in combination with a sulfonylurea and metformin

Very common(may affect more than 1 in 10 people): low blood sugar

Common:constipation

Some patients experienced the following side effects while taking sitagliptin and pioglitazone:

Common:flatulence, swelling of hands or feet

Some patients experienced the following side effects while taking sitagliptin in combination with pioglitazone and metformin:

Common:swelling of hands or feet

Some patients experienced the following side effects while taking sitagliptin in combination with insulin (with or without metformin):

Common:flu

Uncommon:dry mouth

Some patients experienced the following side effects while taking sitagliptin alone during clinical trials, or during use after approval alone and/or with other diabetes medicines:

Common:low blood sugar, headache, upper respiratory tract infection, nasal congestion, and sore throat, arthrosis, pain in the arm or leg

Uncommon: dizziness, constipation, itching

Rare: reduced number of platelets

Frequency not known: kidney problems (which may require dialysis), vomiting, joint pain, muscle pain, back pain, interstitial lung disease, bullous pemphigoid (a type of skin blister)

Reporting of side effects

If you experience any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Spanish Pharmacovigilance System for Human Use Medicines: www.notificaRAM.es.

By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Jidinum

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the blister and carton after EXP. The expiry date is the last day of the month shown.

This medicine does not require any special storage conditions.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.

6. Contents of the pack and other information

Composition of Jidinum

• The active substance is sitagliptin. Each tablet contains sitagliptin hydrochloride monohydrate equivalent to 25 mg, 50 mg, and 100 mg of sitagliptin.
• The other ingredients are:
• tablet core: anhydrous calcium hydrogen phosphate, microcrystalline cellulose, sodium croscarmellose, magnesium stearate, and sodium stearyl fumarate.
• film coating: Opadry II white 85F18422 (polyvinyl alcohol, titanium dioxide (E171), macrogol, talc), red iron oxide (E172) (for 50 mg and 100 mg), yellow iron oxide (E172) (for 25 mg and 100 mg).

Appearance and packaging

Jidinum 25 mg film-coated tablets

Yellow, round, biconvex, film-coated tablets, with the inscription "25" on one side, with a diameter of approximately 6 mm.

Jidinum 50 mg film-coated tablets

Light red, round, biconvex, film-coated tablets, with the inscription "50" on one side, with a diameter of approximately 8 mm.

Jidinum 100 mg film-coated tablets

Light brown, round, biconvex, film-coated tablets, with the logo "MC" engraved on one side, with a diameter of approximately 10 mm.

Blister packs of Polyamide/Aluminum/PVC/Aluminum with 14, 28, 30, 56, 84, 90, 98 tablets.

Not all pack sizes may be marketed.

Marketing authorization holder and manufacturer

Medochemie Ltd.

1-10 Constantinoupoleos Street,

3011 Limassol

Cyprus

You can ask for more information about this medicine from the local representative of the marketing authorization holder:

Local representative:

Medochemie Iberia S.A., Sucursal en España

Avenida de las Águilas, nº 2 B; planta 5 oficina 6,

28044 Madrid

Spain

Date of last revision of this leaflet:December 2021

Detailed information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/